Welcome to our dedicated page for Optimi Health news (Ticker: OPTHF), a resource for investors and traders seeking the latest updates and insights on Optimi Health stock.
Optimi Health Corp. (OPTHF) is a Health Canada-licensed manufacturer specializing in GMP-certified psychedelic substances for therapeutic research. This page provides investors and researchers with verified updates on the company’s regulatory progress, clinical partnerships, and production capabilities.
Access comprehensive coverage of Optimi Health’s developments including export agreements, compliance milestones, and research initiatives. Users will find press releases related to pharmaceutical-grade psilocybin production, MDMA formulation advancements, and international distribution partnerships across regulated markets.
Key updates focus on Health Canada licensing status, GMP manufacturing standards, clinical trial support, and strategic collaborations with global research organizations. All content is curated to meet investor needs for timely, accurate information in the evolving psychedelic pharmaceuticals sector.
Bookmark this page for streamlined access to Optimi Health’s official announcements. Check regularly for updates on regulatory approvals and advancements in psychedelic-assisted therapy research.
Optimi Health Corp. (OTCQX: OPTHF), a Canadian manufacturer of MDMA and naturally-derived psilocybin, has publicly filed a registration statement with the SEC for a proposed U.S. IPO. The company has applied to list its common shares on the Nasdaq Capital Market under the symbol "OPTH".
While the specific number of shares and price range are yet to be determined, Titan Partners Group will serve as the sole book-running manager for the offering. The registration statement (File Number: 333-290086) has been filed but is not yet effective, and securities cannot be sold until it becomes effective.
Optimi Health (OTCQX: OPTHF) has launched natural psilocybin capsules in Australia for treating Treatment-Resistant Depression (TRD) under the Authorised Prescriber Scheme. The company has shipped 1,000 capsules containing 5mg of standardized naturally-derived psilocybin, manufactured at their GMP-licensed facility in British Columbia.
The launch follows Optimi's successful introduction of MDMA sales for PTSD treatment in Australia in October 2024. Mind Medicine Australia, Optimi's commercial partner, will manage distribution and patient coordination through Australian clinics and hospitals, while collecting patient-reported outcome data to build comprehensive real-world evidence for psilocybin treatment.
Optimi Health (OTCQX: OPTHF), a GMP-certified MDMA and psilocybin manufacturer, has announced two significant updates. First, the company has engaged MZ Investor Relations for strategic capital markets support at US$9,000-13,500 monthly, granting them 1.9 million stock options with varying exercise prices and vesting schedules.
On the manufacturing front, Optimi has achieved a milestone by completing production of over 3,000 GMP doses of 5mg natural psilocybin extract capsules. These will be used to treat Treatment-Resistant Depression patients in Australia and supply upcoming Phase 2 clinical trials globally. The company offers GMP-certified MDMA capsules (40mg and 60mg), psilocybin capsules, and APIs to licensed distributors and pharmaceutical companies.
Cathay Visions Enterprises Ltd. has acquired 450 unsecured convertible debentures of Optimi Health Corp. (OTC:OPTHF) at CAD$1,000 per debenture, totaling a CAD$450,000 investment. The debentures feature a 15% annual interest rate, payable quarterly in cash, with a 12-month maturity that can be extended to 24 months.
The debentures are convertible into common shares at $0.15 per share. Prior to this acquisition, Cathay owned 11,875,566 common shares (12.29% ownership). Following the acquisition, Cathay now controls 11,875,566 shares, 533,333 warrants, and 450,000 stock options, representing 12.29% undiluted and 13.71% partially diluted ownership.
["Debentures offer attractive 15% annual interest rate", "Flexibility to convert debentures to equity at $0.15 per share", "Option to extend maturity from 12 to 24 months"]Optimi Health (OTCQX: OPTHF), a Canadian manufacturer of GMP-grade MDMA and natural psilocybin, has announced a CAD$3.45 million convertible debenture financing and the extension of a secured term loan. The convertible debentures, priced at CAD$1,000 each, will bear a 15% annual interest rate and are convertible into common shares at $0.15 per share.
The company has also extended its CAD$1 million secured term loan to April 30, 2026, which carries a 7.5% annual interest rate. As part of the loan extension, Optimi issued 400,000 warrants exercisable at $0.25 per share for two years.
The convertible financing involves two insiders: CEO Dane Stevens and Board Chair JJ Wilson, who will hold 12.29% and 8.52% of the company respectively post-transaction.
Optimi Health (OPTHF) has completed its largest international MDMA export to Australia, delivering 1,000 GMP-certified capsules for PTSD treatment. The shipment, conducted with Mind Medicine Australia, includes both 40mg and 60mg strength capsules and received approval from Australia's Therapeutic Goods Administration (TGA) and Health Canada.
In a significant development, the Australian Department of Veterans' Affairs (DVA) has announced it will fund MDMA-assisted therapy for veterans diagnosed with PTSD, marking the first time a federal agency in Australia has committed to reimbursing psychedelic-assisted treatment. The capsules will be distributed through authorized pharmacy networks and clinics across Australia under Optimi's Drug Establishment Licence (DEL).
Optimi Health (OPTHF) has received its U.S. FDA Establishment Identifier (FEI) number, marking a significant regulatory milestone that enables the company to supply GMP-certified MDMA and psilocybin to authorized entities in the United States. The registration positions Optimi as an FDA-recognized pharmaceutical manufacturer capable of producing both active ingredients and finished drug products.
Operating from its Canada-based facility with a Health Canada Drug Establishment License (DEL), Optimi can now engage in FDA filings and participate in the U.S. pharmaceutical supply chain. The company's capabilities include manufacturing pharmaceutical-grade MDMA and psilocybin in both API form and encapsulated drug products. This development is particularly timely as 25 U.S. states have considered psychedelic legislation through more than 74 bills.
Optimi Health (OTCQX: OPTHF), a GMP-compliant manufacturer of botanical psilocybin and MDMA, has announced several key developments. The company has secured additional import permits for 1,000 doses of GMP MDMA capsules in Australia, following previous shipments of 860 doses in 2024.
The company obtained a important BICON import permit for natural psilocybin extract capsules in Australia, enabling authorized prescribers to access their treatment for resistant depression. A partnership with ATMA CENA Healthcare Solutions has been established for Phase 2 clinical trials, testing psilocybin-assisted therapy for major depressive disorder in 200 patients, with dosing beginning Q2 2025.
Optimi recently completed a harvest of high-potency Psilocybe cubensis for GMP extraction and 5mg dose encapsulation. The company maintains over 200 natural psilocybin genetic varieties. Additionally, Optimi will issue 100,000 common shares for advisory services and settle $20,000 in fees through share issuance, both subject to a four-month hold period.
Optimi Health Corp (CSE: OPTI) (OTCQX: OPTHF) has completed its largest MDMA production batch to date, manufacturing over 4,000 GMP capsules capable of treating more than 1,000 patients. The company has achieved significant milestones in its stability program, validating a one-year shelf life for previously manufactured MDMA capsules and launching a two-year stability program.
The production will support PTSD treatment across multiple markets including Australia, Israel, and Canada. The company is currently supporting a Phase 2 clinical trial for PTSD in Israel, fulfilling Special Access Program requests in Canada, and supplying Australian patients through the Authorized Prescriber Scheme.
Optimi's in-house manufacturing capabilities, combined with its secure storage capacity for up to CAD $50 million worth of scheduled substances, positions the company to meet increasing market demand. The company reports that its MDMA offering is more cost-effective compared to market alternatives.
Optimi Health Corp. (OPTHF) has announced two key financial updates. First, the company plans to close a second and final tranche of a non-brokered private placement, issuing 131,666 units at CAD$0.30 per unit for gross proceeds of CAD$395,000. Each unit includes one common share and half of a transferable purchase warrant exercisable at CAD$0.40 for two years.
The warrants include an accelerated expiry provision if the company's stock price exceeds CAD$0.50 for 20 consecutive trading days. The offering involves insider participation and will be used for general working capital. Additionally, Optimi is completing a debt settlement with two creditors, converting CAD$98,126.25 of marketing and investor relations services debt into common shares.
Both transactions are expected to close around January 24, 2025, with securities subject to a standard 4-month hold period.
FAQ
What is the current stock price of Optimi Health (OPTHF)?
What is the market cap of Optimi Health (OPTHF)?
